Compare Abeona Therapeutics Inc (ABEO) vs Costco Wholesale Corporation (COST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Costco Wholesale Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Costco Wholesale Corporation trades at $942.2 (market cap $420.20B). The key difference: Costco Wholesale Corporation is far larger — about 1125.6× Abeona Therapeutics Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | COST | |
|---|---|---|
Market Cap | $373.32M | $420.20B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $1.09K |
52-Week Low | $4.17 | $849.63 |
Enterprise Value | $228.22M | $408.34B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Costco (COST) trades at $953.13, up 0.3% on the day, with a bearish technical signal but strong fundamentals including consistent revenue growth to $275.24B in 2025 and net income of $8.10B. Recent March sales surged 11.3% year-over-year, and the company announced a dividend of $1.47 payable in May 2026. Valuation metrics remain elevated with a P/E of 47.66, while analyst consensus is strongly bullish with a $1,110 price target.
The outlook is positive due to robust membership fee growth and expansion potential, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is solid despite a recent Q1 2026 miss, with Q2 2026 expected at $6.56 EPS. Institutional ownership trends show increased stakes, supporting confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →
